Patents Assigned to AstraZeneca
  • Therapeutic dendrimers
    Patent number: 10314920
    Abstract: Disclosed are dendrimers of formula (I): and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising the dendrimer of formula (I) and methods of using the same for treating cancer.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: June 11, 2019
    Assignee: AstraZeneca AB
    Inventors: Marianne Bernice Ashford, Iain Grant, Edward John Hennessy, William McCoull, Michael Giannis, Brian Kelly, David Owen, John Paul Secrist
  • bis-Pyridazine Compounds and Their Use in Treating Cancer
    Publication number: 20190169172
    Abstract: A compound of Formula (I): or a pharmaceutically where R1 can be hydro, methoxy, difluoromethoxy or trifluoromethoxy; R2 can be hydro, methoxy, trifluoromethoxy or trifluoromethyl; and R3 can be hydro or methoxy. The compound of formula (I) can inhibit glutaminase, e.g., GLS1.
    Type: Application
    Filed: February 4, 2019
    Publication date: June 6, 2019
    Applicants: AstraZeneca AB, Cancer Research Technology Limited
    Inventor: Maurice Raymond Verschoyle Finlay
  • Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction
    Patent number: 10300065
    Abstract: The present disclosure relates to methods for reducing the rate of cardiovascular death, myocardial infarction, or stroke in a patient in recognized need thereof, comprising administering to the patient a pharmaceutical composition comprising 60 mg ticagrelor twice daily.
    Type: Grant
    Filed: January 27, 2016
    Date of Patent: May 28, 2019
    Assignee: ASTRAZENECA AB
    Inventors: Lars Magnus Andersson, Tomas Lars-Gunnar Andersson, Olof Fredrik Bengtsson, Hans Peter Held, Garnet Edward Howells, Eva Christina Jensen, Robert Storey
  • Anti-IFNAR1 antibodies with reduced Fc ligand affinity
    Patent number: 10301390
    Abstract: The invention provides anti-IFNAR1 antibodies with reduced affinity for Fc receptors and/or ligands and methods of making and using such antibodies.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: May 28, 2019
    Assignee: AstraZeneca AB
    Inventors: Anthony Coyle, Peter Kiener, Herren Wu, Ricardo Cibotti
  • Compounds
    Patent number: 10301267
    Abstract: There is provided a compound of formula (I): or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: May 28, 2019
    Assignee: AstraZeneca AB
    Inventors: David Buttar, Kevin Michael Foote, Maria-Elena Theoclitou, Andrew Peter Thomas
  • 1, 3, 4-thiadiazole compounds and their use in treating cancer
    Patent number: 10294221
    Abstract: The specification relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, where Q, R, R1 and R2 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent GLS1 mediated disease, including cancer. The specification further relates to crystalline forms of compounds of Formula (I) and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating GLS1 kinase mediated disease, including cancer, using such compounds and salts.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: May 21, 2019
    Assignees: AstraZeneca AB, Cancer Research Technology Limited
    Inventors: Maurice Raymond Verschoyle Finlay, Chukuemeka Tennyson Ekwuru, Mark David Charles, Piotr Antoni Raubo, Jonathan James Gordon Winter, Johannes Wilhelmus Maria Nissink
  • Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors
    Patent number: 10287258
    Abstract: The present disclosure relates to certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Grant
    Filed: September 19, 2017
    Date of Patent: May 14, 2019
    Assignee: ASTRAZENECA AB
    Inventors: Hans Roland Lonn, Stephen Connolly, Steven Swallow, Staffan Po Karlsson, Carl-Johan Aurell, John Fritiof Pontén, Kevin James Doyle, Amanda Jane Van De Poël, Graham Peter Jones, David Wyn Watson, Jaqueline Anne Macritchie, Nicholas John Palmer
  • Arginase Inhibitors and Methods of Use
    Publication number: 20190127395
    Abstract: The present invention is directed to arginase inhibitor compounds of formula IA or formula IB: or a pharmaceutically acceptable salt thereof, compositions containing these compounds, and methods of their use for the treatment and diagnosis of conditions characterized by upregulation of arginase, abnormally high arginase activity, or by abnormally low nitric oxide synthase activity.
    Type: Application
    Filed: September 28, 2018
    Publication date: May 2, 2019
    Applicants: AstraZeneca AB, The Trustees of the University of Pennsylvania
    Inventors: David W. Christianson, Bruce Edward Tomczuk, Richard Scott Pottorf, Andrew Vargha Colasanti, Gary Lee Olson
  • C5-anilinoquinazoline compounds and their use in treating cancer
    Patent number: 10273227
    Abstract: The invention concerns compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, R3 and R4 have any of the meanings hereinbefore defined in the description; process for their preparation; pharmaceutical compositions containing them and their use in treating KIT mediated diseases.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: April 30, 2019
    Assignee: AstraZeneca AB
    Inventors: Jason Kettle, Stuart Pearson, Martin Packer, James Smith
  • PHARMACEUTICAL COMPOSITIONS COMPRISING AZD9291
    Publication number: 20190111057
    Abstract: The present invention relates to pharmaceutical compositions suitable for oral administration, and more particularly to pharmaceutical compositions, including pharmaceutical tablet compositions, containing N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide (“AZD9291”) or a pharmaceutically acceptable salt thereof, wherein such compositions comprise a certain amount of microcrystalline cellulose and at least one other pharmaceutical diluent.
    Type: Application
    Filed: November 20, 2018
    Publication date: April 18, 2019
    Applicant: AstraZeneca AB
    Inventors: Cindy FINNIE, Steven Anthony RAW, David WILSON
  • THERAPEUTIC POLYMERIC NANOPARTICLES AND METHODS OF MAKING AND USING SAME
    Publication number: 20190092757
    Abstract: Described herein are polymeric nanoparticles that include a therapeutic agent which is 2-(3-((7-(3-(ethyl(2-hydroxyethyl)amino)propoxy)quinazolin-4-yl)amino)-1H-pyrazol-5-yl)-N-(3-fluorophenyl)acetamide (also known as AZD1152 hqpa) or a pharmaceutically acceptable salt thereof, and methods of making and using such therapeutic nanoparticles.
    Type: Application
    Filed: June 27, 2018
    Publication date: March 28, 2019
    Applicant: ASTRAZENECA AB
    Inventors: Marianne Bernice ASHFORD, James Martin NOLAN, III, Eyoung SHIN, Young-Ho SONG, Greg TROIANO, Hong WANG
  • 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS
    Publication number: 20190092746
    Abstract: The present invention relates to certain 2-(2,4,5-substituted-anilino)pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the L858R activating mutant, the Exon19 deletion activating mutant and the T790M resistance mutant). Such compounds and salts thereof may be useful in the treatment or prevention of a number of different cancers. The invention also relates to pharmaceutical compositions comprising said compounds and salts thereof, especially useful polymorphic forms of these compounds and salts, intermediates useful in the manufacture of said compounds and to methods of treatment of diseases mediated by various different forms of EGFR using said compounds and salts thereof.
    Type: Application
    Filed: May 29, 2018
    Publication date: March 28, 2019
    Applicant: AstraZeneca AB
    Inventors: Sam Butterworth, Maurice Raymond Verschoyle Finlay, Richard Andrew Ward, Heather Marie Redfearn, Vasantha Krishna KADAMBAR, Chandrashekar Reddy C MURUGAN, Andiappan MURUGAN
  • CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING BRONCHIECTASIS
    Publication number: 20190091236
    Abstract: The present disclosure relates to methods for treating bronchiectasis, for example, non-cystic fibrosis bronchiectasis with compositions comprising an effective amount of certain (2S)—N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds of Formula (I), including pharmaceutically acceptable salts thereof, that inhibit dipeptidyl peptidase 1 (DPP1) activity. Methods provided herein are useful for prophylaxis, increasing the lung function in a patient, and/or and/or decreasing the rate of pulmonary exacerbation in a patient. In one embodiment, the compound of Formula (I) is (2S)—N-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide.
    Type: Application
    Filed: November 21, 2018
    Publication date: March 28, 2019
    Applicants: AstraZeneca AB, Insmed Incorporated
    Inventors: Hans Roland Lonn, Stephen Connolly, Steven Swallow, Reinilde Heyrman, Eugene Sullivan, Carlos Fernandez
  • NOVEL COMPOUNDS
    Publication number: 20190084934
    Abstract: The present specification provides a compound of formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ROR? and/or ROR?t mediated disease state.
    Type: Application
    Filed: June 4, 2018
    Publication date: March 21, 2019
    Applicant: AstraZeneca AB
    Inventors: Frank Narjes, Roine Ingemar Olsson, Stefan Von Berg, Sarah Lever
  • PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS
    Publication number: 20190084991
    Abstract: The present application relates to novel compounds of formula (I) to their utility in treating and/or preventing clinical conditions including cardiovascular diseases (CVD), to methods for their therapeutic use, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Application
    Filed: November 20, 2018
    Publication date: March 21, 2019
    Applicant: ASTRAZENECA AB
    Inventors: Johan Olof BRODDEFALK, Hans Fredrik EMTENÂS, Kenneth Lars GRANBERG, Malin Anita LEMURELL, Daniel Tor PETTERSEN, Alleyn Thomas PLOWRIGHT, Lars Johan Andreas ULANDER
  • Tear lipocalin muteins binding IL-4 R alpha
    Patent number: 10232014
    Abstract: The present invention relates to novel muteins derived from human tear lipocalin, which bind to IL 4 receptor alpha. The sequences of the muteins comprise particular combinations of amino acids. In particular a mutated amino acid residue is present at any one or more of the sequence positions 27, 28 30, 31, 33, 53, 57, 61, 64, 66, 80, 83, 104-106 and 108 of the linear polypeptide sequence of the mature human tear lipocalin. A mutated amino acid residue is also present at any 2 or more of the sequence positions 26, 32, 34, 55, 56, 58 and 63 of the linear polypeptide sequence of the mature human tear lipocalin. The invention also provides a corresponding nucleic acid molecule encoding such a mutein and a method for producing such a mutein and its encoding nucleic acid molecule.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: March 19, 2019
    Assignees: PIERIS PHARMACEUTICALS GMBH, ASTRAZENECA AB
    Inventors: Andreas Hohlbaum, Alexandra Baehre, Gabriele Matschiner, Stefan Trentmann, Klaus Kirchfeld, Hans-Juergen Christian
  • Compounds and their use as BACE inhibitors
    Patent number: 10231967
    Abstract: The present invention relates to compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of A?-related pathologies such as Down's syndrome, ?-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: March 19, 2019
    Assignee: AstraZeneca AB
    Inventors: Gabor Csjernyik, Sofia Karlstrom, Annika Kers, Karin Kolmodin, Martin Nylof, Liselotte Ohberg, Laszlo Rakos, Lars Sandberg, Fernando Sehgelmeble, Peter Soderman, Britt-Marie Swahn, Stefan Von Berg
  • Chemical compounds
    Patent number: 10221173
    Abstract: The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of cell proliferative disorders.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: March 5, 2019
    Assignee: AstraZeneca AB
    Inventors: Johannes Wilhelmus Maria Nissink, James Stewart Scott, Thomas Andrew Moss, Samantha Jayne Hughes, Bernard Christophe Barlaam, Bin Yang
  • NMDA antagonist prodrugs
    Patent number: 10207994
    Abstract: Prodrugs of an NMDA antagonist, (S)-1-phenyl-2-(pyridin-2-yl)ethanamine, useful for the treatment of depression (particularly major depressive disorder) or pain; compositions comprising them, and methods of making them.
    Type: Grant
    Filed: October 17, 2017
    Date of Patent: February 19, 2019
    Assignee: AstraZeneca AB
    Inventors: Gunnar Nordvall, Katharina Högdin, Per Jonas Malmborg, Annika Kers, Dirk Reinhold Weigelt, Peter Robert Bernstein, Michael Quirk, Michael Balestra
  • Chemical compounds
    Patent number: 10202391
    Abstract: The present disclosure concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1, R2 and R3 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cancer.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: February 12, 2019
    Assignee: AstraZeneca AB
    Inventors: Clifford David Jones, Richard Andrew Ward, Mark Andrew Graham, Steven Swallow, Andrew Hornby Dobson, James Francis McCabe